A phase 2 trial evaluating atuzaginstat (COR388) for oral/head and neck squamous cell cancer (O/HNSCC)
Latest Information Update: 14 Mar 2022
At a glance
- Drugs Atuzaginstat (Primary)
- Indications Head and neck cancer; Mouth neoplasm; Squamous cell cancer
- Focus Therapeutic Use
Most Recent Events
- 14 Mar 2022 New trial record
- 09 Mar 2022 According to a Cortexyme media release, company has completed a pre-IND meeting with U.S. Food and Drug Administration (FDA) and plans to submit an IND to the Division of Oncology 2 in the first half of 2022.